natgillin/translations-raw huggingface dataset:
Phenotypic analysis showed no significant changes in emtricitabine susceptibility unless the M184V/I mutation had developed. 
Fenotipska analiza ni pokazala bistvenih sprememb v občutljivosti za emtricitabin, razen če se je razvila mutacija M184V/I.
If you have hepatitis B infection, your doctor will carefully consider the best treatment regimen for you. 
Če ste okuženi s hepatitisom B, bo vaš zdravnik skrbno razmislil o najboljšem režimu zdravljenja za vas.
Keep the carton with you so that you can easily describe what you have taken. 
S seboj imejte škatlo, da boste lahko opisali, kaj ste zaužili.
Adults with renal insufficiency 
Odrasli z ledvično insuficienco
Although the mean Cmax and Cmin were approximately 20% higher and mean AUC was 16% higher in females compared to males, this difference was not considered clinically significant. 
Čeprav je bila povprečna vrednost Cmax in Cmin pri ženskah višja za približno 20 % in povprečna vrednost AUC višja za 16 % kot pri moških, ta razlika ni klinično pomembna.
* Assumes a 3-hour haemodialysis session three times a week commencing at least 12 h after administration of the last dose of emtricitabine. 
* Predpostavlja 3-urno hemodializo trikrat tedensko, z začetkom vsaj 12 ur po uporabi zadnjega odmerka emtricitabina.
The frequency category of uncommon was estimated from a statistical calculation based on the total number of patients exposed to emtricitabine in these clinical studies (n = 1,563). 
Kategorija pogostnosti občasna je bila ocenjena s statističnim izračunom na podlagi skupnega števila bolnikov, izpostavljenih emtricitabinu v teh kliničnih študijah (n = 1.563).
In general, the pharmacokinetics of emtricitabine in infants, children and adolescents (aged 4 months up to 18 years) are similar to those seen in adults. 
Na splošno so farmakokinetične lastnosti emtricitabina pri dojenčkih, otrocih in mladostnikih (v starosti od 4 mesecev do 18 let) podobne tistim, ki so bile opažene pri odraslih.
Ethnicity No clinically important pharmacokinetic difference due to ethnicity has been identified. 
Etnična pripadnost Ni bilo identificirane klinično pomembne farmakokinetične razlike glede na etnično pripadnost.
Emtriva [outer packaging only] 
Emtriva [samo na zunanji ovojnini]
This is because the active substance in this medicine passes into human breast milk. 
To je zato, ker zdravilna učinkovina tega zdravila prehaja v materino mleko.
After opening: The solution should be used within 45 days. 
Po odprtju: Raztopina mora biti uporabljena v roku 45 dni.
Up to 30% of the emtricitabine dose can be removed by haemodialysis. 
Do 30 % odmerka emtricitabina se lahko odstrani s hemodializo.
If you experience dizziness while taking Emtriva, do not drive and do not use any tools or machines. 
Če ste v času zdravljenja z uporabo zdravila Emtriva omotični, ne vozite avtomobila in ne upravljajte z orodji ali stroji.
Blisters made of polychlorotrifluorethylene (PCTFE) / polyethylene (PE) / polyvinylchloride (PVC) / aluminium. 
Pretisni omot je narejen iz poliklorotrifluoretilena (PCTFE)/polietilena (PE)/polivinilklorida (PVC)/ aluminija.
It must be used in combination with other antiretrovirals. 
Uporabljati se mora v kombinaciji z drugimi protiretrovirusnimi zdravili.
• If you could get pregnant during treatment with Emtriva, you must use an effective method of contraception to stop you getting pregnant. 
• Če bi lahko med zdravljenjem z zdravilom Emtriva zanosili, morate uporabljati učinkovito kontracepcijsko metodo, ki preprečuje zanositev.
A moderate amount of data on pregnant women (between 300 and1,000 pregnancy outcomes) indicate no malformations or foetal/neonatal toxicity associated with emtricitabine. 
Manjše število podatkov pri nosečnicah (med 300 in 1.000 izpostavljenih nosečnosti) ne kaže na malformacije ali feto/neonatalno toksičnost, povezane z emtricitabinom.
• You must not take Emtriva during pregnancy unless specifically directed by your doctor. 
• Zdravila Emtriva ne smete jemati med nosečnostjo, razen če je to posebej odredil vaš zdravnik.
Therefore Emtriva is not recommended for use in those aged less than 4 months (for pharmacokinetic data in this age group, see section 5.2). 
Zato se uporaba zdravila Emtriva pri bolnikih, mlajših od 4 mesecev ne priporoča (za farmakokinetične podatke v tej starostni skupini glejte poglavje 5.2).
The safety and efficacy of the dose interval adjustments to every 72 or 96 hours in patients with creatinine clearance < 30 mL/min have not been clinically evaluated. 
Varnost in učinkovitost teh prilagoditev intervala odmerjanja na vsakih 72 ali 96 ur pri bolnikih z očistkom kreatinina < 30 ml/min še nista bili klinično ovrednoteni.
It is not known whether emtricitabine can be removed by peritoneal dialysis. 
Ni znano, ali se lahko emtricitabin odstrani s peritonealno dializo.
If the production of red blood cells is reduced, a child may have symptoms of tiredness or breathlessness. 
Če je tvorba rdečih krvnih telesc zmanjšana, se pri otroku lahko pojavijo znaki utrujenosti ali zadihanosti.
Although there are limited clinical data on the use of Emtriva in pregnant women, it is not usually used unless absolutely necessary. 
Čeprav so na voljo nezadostni klinični podatki o uporabi zdravila Emtriva pri nosečnicah, se zdravila Emtriva ponavadi ne uporablja, razen če je nujno potrebno.
Other medicines and Emtriva 
Druga zdravila in zdravilo Emtriva
There is insufficient evidence to determine whether re-initiation of emtricitabine alters the course of post-treatment exacerbations of hepatitis. 
Ni dovolj dokazov, s katerimi bi določili, ali je ponoven začetek zdravljenja z emtricitabinom spremenil potek poslabšanja hepatitisa po zdravljenju.
The systemic clearance of emtricitabine averaged 307 mL/min (4.03 mL/min/kg). 
Sistemski očistek emtricitabina je v povprečju 307 ml/min (4,03 ml/min/kg).
If it is almost time (less than 12 hours) for your next dose anyway, forget about the missed dose. 
Če je že skoraj čas za vaš naslednji odmerek (manj kot 12 ur), pozabljenega odmerka ne vzemite.
• dizziness, weakness, difficulty sleeping, abnormal dreams 
• omotica, oslabelost, težave s spanjem, nenavadne sanje
The YMDD mutation confers resistance to both emtricitabine and lamivudine. 
Mutacija YMDD povzroča odpornost tako na emtricitabin kot na lamivudin.
The use of emtricitabine may be considered during pregnancy, if necessary. 
Če je potrebno, se lahko pretehta možnost uporabe emtricitabina med nosečnostjo.
If there is evidence of exacerbations of liver disease in such patients, interruption or discontinuation of treatment must be considered. 
Če se opazi poslabšanje obolenja jeter pri teh bolnikih, je potrebno razmisliti o prekinitvi ali prenehanju tovrstnega zdravljenja.
• Your doctor will prescribe Emtriva with other antiretroviral medicines. 
• Zdravnik vam bo predpisal zdravilo Emtriva skupaj z drugimi protiretrovirusnimi zdravili.
If you have taken Emtriva during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child. 
Če ste zdravilo Emtriva jemali med nosečnostjo, vas lahko zdravnik naroči na redne preiskave krvi in druge diagnostične preiskave, da bo nadzoroval razvoj vašega otroka.
Animal studies do not indicate harmful effects of emtricitabine on fertility. 
Študije na živalih ne kažejo škodljivih učinkov emtricitabina na plodnost.
Emtriva may lower the amount of HIV in the blood (viral load). 
Zdravilo Emtriva lahko zniža prisotnost virusa HIV v krvi (viral load).
After first opening: 45 days. 
45 dni od prvega odprtja.
As a general rule, it is recommended that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV to the infant. 
Splošno priporočljivo je, naj s HIV okužene ženske v nobenem primeru ne dojijo, da se prepreči prenos HIV na dojenčka.
The adverse reactions with suspected (at least possible) relationship to treatment in adults from clinical trial and post-marketing experience are listed in Table 2 below by body system organ class and frequency. 
Neželene reakcije z domnevno (vsaj možno) zvezo z zdravljenjem pri odraslih bolnikih iz klinične študije in izkušenj v obdobju trženja zdravila so navedene spodaj v preglednici 2 glede na organske sisteme in frekvenco.
• headache, diarrhoea, feeling sick (nausea) 
• glavobol, driska, občutek siljenja na bruhanje (navzea)
You should not take Emtriva if you are already taking other medicines that contain emtricitabine or lamivudine, which are also used to treat HIV infection, unless otherwise directed by your doctor. 
Zdravila Emtriva ne smete jemati, če že jemljete druga zdravila, ki vsebujejo emtricitabin ali lamivudin, ki se prav tako uporabljajo za zdravljenje okužbe z virusom HIV, razen če vaš zdravnik ne odredi drugače.
Where available, resistance testing may be appropriate. 
Kadar je le mogoče, je predhodno priporočljivo opraviti test rezistence.
However, limited data are available on the efficacy and safety of emtricitabine (as a 200 mg hard capsule once daily) in patients who are co-infected with HIV and HBV. 
Vendar pa so na voljo omejeni podatki o učinkovitosti in varnosti uporabe emtricitabina (v obliki 200 mg trde kapsule enkrat dnevno) pri bolnikih s hkratno okužbo s HIV in HBV.
Intracellular pharmacokinetics: In a clinical study, the intracellular half-life of emtricitabine-triphosphate in PBMCs was 39 hours. 
Znotrajcelične farmakokinetične lastnosti: V kliničnih študijah je bila znotrajcelična razpolovna doba emtricitabin-trifosfata v PBMC 39 ur.
Stopping treatment with Emtriva may reduce the effectiveness of the anti-HIV therapy recommended by your doctor. 
Prenehanje zdravljenja z zdravilom Emtriva lahko zmanjša učinkovitost zdravljenja okužbe s HIV, ki vam ga je predpisal zdravnik.
It is advised to write the date of removal from the refrigerator on the package. 
Priporočljivo je, da na ovojnino zapišete datum, ko ste zdravilo vzeli iz hladilnika.
Administration of up to 1,200 mg emtricitabine has been associated with the adverse reactions listed above (see section 4.8). 
Uporabo do maksimalno 1.200 mg emtricitabina spremljajo neželeni učinki, navedeni zgoraj (glejte poglavje 4.8).
Table 2: Tabulated summary of adverse reactions associated with emtricitabine based on clinical study and post-marketing experience 
Preglednica 2: Povzetek neželenih reakcij, povezanih z emtricitabinom na podlagi izkušenj iz kliničnih študij in izkušenj v obdobju trženja zdravila
Tell your doctor about any of the following side effects: Most frequent side effects 
Obvestite zdravnika, če imate kateregakoli od naslednjih neželenih učinkov: Najpogostejši neželeni učinki
Pharmacotherapeutic group: Nucleoside and nucleotide reverse transcriptase inhibitors, ATC code: J05AF09 
Farmakoterapevtska skupina: Nukleozidni in nukleotidni zaviralci reverzne transkriptaze, oznaka ATC: J05AF09
This dose is half of that approved for infants aged 4 months and over (6 mg/kg). 
To je polovica odmerka, odobrenega za dojenčke, stare 4 mesece ali več (6 mg/kg).
This HIV-1 mutation was observed in vitro and in HIV-1 infected patients. 
Ta mutacija virusa HIV-1 je bila opažena in vitro in pri bolnikih, okuženih z virusom
Emtricitabine is active in vitro against HBV. 
Emtricitabin je aktiven in vitro proti virusu HBV.
Make sure that you understand how to measure and give the right amount of oral solution according to the weight of the person being treated. 
Prepričajte se, da znate pravilno odmeriti in uporabiti ustrezno količino peroralne raztopine ob upoštevanju telesne mase zdravljenega bolnika.
It is important not to miss a dose of Emtriva. 
Pomembno je, da ne pozabite vzeti nobenega odmerka zdravila Emtriva.
Do not take a double dose to make up for a forgotten hard capsule. 
Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnjo trdo kapsulo.
Elderly: There are no safety and efficacy data available in patients over the age of 65 years. 
Starostniki: Ni razpoložljivih podatkov o varnosti in učinkovitosti uporabe pri bolnikih, starejših od 65 let.
A measuring cup is provided (see section 6.5). 
Merica je priložena (glejte poglavje 6.5).
Patients co-infected with HBV 
Bolniki, ki so okuženi hkrati še s HBV
However, no adjustment in the recommended daily dose for adults should be required unless there is evidence of renal insufficiency. 
Vendar za odrasle ni potrebno prilagajanje priporočenega dnevnega odmerka razen v primeru ledvične insuficience.
Based on the results of these in vitro experiments and the known elimination pathways of emtricitabine, the potential for CYP450 mediated interactions involving emtricitabine with other medicinal products is low. 
Ob upoštevanju rezultatov tovrstnih in vitro poskusov in znanih poti izločanja emtricitabina je možnost CYP450 posredovanih interakcij, ki vključujejo emtricitabin skupaj z drugimi zdravili, majhna.
In some of these patients, HBV reactivation was associated with more severe liver disease, including decompensation and liver failure. 
Pri nekaterih od teh bolnikov je bila reaktivacija virusa HBV povezana s hujšo boleznijo jeter, vključno z dekompenzacijo in odpovedjo delovanja jeter.
If you have a history of liver disease or chronic hepatitis B infection your doctor may conduct blood tests in order to carefully monitor liver function. 
Če ste imeli jetrne bolezni ali okužbo s kroničnim hepatitisom B, bo vaš zdravnik morda opravil krvne preiskave za skrbno nadzorovanje jetrne funkcije.
Assessment of adverse reactions from clinical study data is based on experience in three studies in adults (n = 1,479) and three paediatric studies (n = 169). 
Ugotavljanje neželenih reakcij iz podatkov kliničnih študij temelji na izkušnjah treh študij z odraslimi bolniki (n = 1.479) in treh pediatričnih študij (n = 169).
When deciding on a new regimen for patients who have failed an antiretroviral regimen, careful consideration should be given to the patterns of mutations associated with different medicinal products and the treatment history of the individual patient. 
Pri določanju novega režima zdravljenja pri bolnikih z neuspešnim predhodnim protiretrovirusnim režimom je potrebno posebno pozornost nameniti vzorcem mutacij kot posledic uporabe različnih zdravil in poteku zdravljenj pri posameznem bolniku.
However, patients should be informed that dizziness has been reported during treatment with emtricitabine. 
Vendar je bolnike potrebno opozoriti, da se lahko v času zdravljenja z emtricitabinom pojavi omotica.
In case of concomitant antiviral therapy for hepatitis B or C, please also refer to the relevant Summary of Product Characteristics for these medicinal products. 
V primeru spremljajočega antivirusnega zdravljenja okužbe s hepatitisom B ali C, upoštevajte prosimo ustrezen povzetek glavnih značilnosti za ta zdravila.
Contents of the pack and other information What Emtriva contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Emtriva
Relevant examples include cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis jirovecii pneumonia. 
Ustrezni primeri vključujejo citomegalovirusni retinitis, generalizirane in/ali žariščne mikobakterijske okužbe in s Pneumocystis jirovecii povzročena pljučnica.
If you are older than this and are prescribed Emtriva, your doctor will monitor you carefully. 
Če ste starejši od 65 let in so vam predpisali zdravilo Emtriva, vas bo zdravnik skrbno nadzoroval.
Therefore Emtriva should not be used during breastfeeding. 
Zato se zdravilo Emtriva med dojenjem ne sme uporabljati.
The clear solution is orange to dark orange in colour. 
Prozorna raztopina je oranžne do temno oranžne barve.
There is no clinical experience of the use of emtricitabine in infants less than 4 months of age. 
Ni kliničnih izkušenj z uporabo emtricitabina pri dojenčkih, mlajših od 4 mesecev.
Emtriva should always be combined with other medicines to treat HIV infection. 
Zdravilo Emtriva je treba vedno kombinirati z drugimi zdravili za zdravljenje okužbe z virusom HIV.
Such exacerbations have been seen following discontinuation of emtricitabine treatment in HBV infected patients without concomitant HIV infection and have been detected primarily by serum alanine aminotransferase (ALT) elevations in addition to re-emergence of HBV DNA. 
Takšno poslabšanje je bilo opaženo po prekinitvi zdravljenja z emtricitabinom pri bolnikih z okužbo s HBV brez hkratne okužbe z virusom HIV in je bilo primarno odkrito s povišanjem serumskega nivoja alanin-aminotransferaze (ALT) z dodatnim ponovnim pojavom HBV DNA.
Steady-state trough plasma concentrations reached levels approximately 4-fold above the in vitro IC90 values for anti-HIV activity. 
Doseženo najnižje stanje dinamičnega ravnovesja plazemskih koncentracij (steady-state trough plasma concentrations) je bilo približno 4-krat nad in vitro IC90 vrednostmi za anti-HIV aktivnost.
• being sick (vomiting), problems with digestion resulting in discomfort after meals, stomach pain 
• bruhanje, prebavne motnje, ki privedejo do slabega počutja po zaužitem obroku, bolečina v trebuhu
Other possible effects 
Drugi možni učinki
The use of emtricitabine in patients with chronic HBV induces the same mutation pattern in the YMDD motif observed with lamivudine therapy. 
Uporaba emtricitabina pri bolnikih s kronično okužbo z virusom HBV povzroča enak vzorec mutacij v motivu YMDD, kot je opažen pri terapiji z lamivudinom.
• Adults: Your doctor will advise the correct amount of Emtriva oral solution to be taken. 
• Odrasli: Vaš zdravnik vam bo predpisal ustrezno količino peroralne raztopine Emtriva, ki jo morate jemati.
Sunset yellow (E110) may cause allergic reactions. 
Oranžno FCF (E110) lahko povzroči alergijske reakcije.
Following oral administration, the elimination half-life of emtricitabine is approximately 10 hours. 
Po peroralni uporabi zdravila je razpolovna doba emtricitabina približno 10 ur.
• Infants, children and adolescents weighing 40 kg or less: the dose of Emtriva 10 mg/mL oral solution is calculated according to your body weight. 
• Dojenčki, otroki in mladostniki s telesno maso nižjo od 40 kg: odmerek peroralne raztopine Emtriva 10 mg/ml je izračunan na osnovi vaše telesne mase.
Some patients have had blood tests or symptoms indicating that their hepatitis has got worse after stopping Emtriva. 
Krvne preiskave ali simptomi pri nekaterih bolnikih so kazali, da se je njihov hepatitis poslabšal po prenehanju zdravljenja z zdravilom Emtriva.
3 This adverse reaction, which was identified through post-marketing surveillance, was not observed in randomised controlled clinical trials in adults or paediatric HIV clinical trials of emtricitabine. 
3 To neželeno reakcijo, ki je bila opredeljena v okviru nadzora v obdobju trženja zdravila, niso opazili v randomiziranih kontroliranih kliničnih študijah pri odraslih ali pediatričnih bolnikih, okuženih z virusom HIV.
In general, emtricitabine pharmacokinetics in HBV infected subjects were similar to those in healthy subjects and in HIV infected subjects. 
Na splošno je bila farmakokinetika emtricitabina pri osebah, okuženih z virusom HBV, zelo podobna tisti pri zdravih osebah in osebah, okuženih z virusom HIV.
In antiretroviral treatment-naïve adults, emtricitabine was significantly superior to stavudine when both medicinal products were taken in combination with didanosine and efavirenz through 48 weeks of treatment. 
Pri odraslih, ki se s protiretrovirusnim zdravilom zdravijo prvič, je bil emtricitabin opazno močnejši od stavudina, ko sta bili obe zdravili uporabljeni v kombinaciji z didanozinom in efavirenzom v času 48-tedenskega zdravljenja.
In clinical trials of HIV infected adults, the most frequently occurring adverse reactions to emtricitabine were diarrhoea (14.0%), headache (10.2%), elevated creatine kinase (10.2%) and nausea (10.0%). 
V kliničnih študijah odraslih bolnikov, okuženih z virusom HIV, so bile najpogostejše neželene reakcije na emtricitabin driska (14,0 %), glavobol (10,2 %), povišanje kreatin-kinaze (10,2 %) in navzea (10,0 %).
If there is any solution left in the bottle after 45 days, this should be disposed of in accordance with local requirements or returned to the pharmacy. 
Če vam je po 45 dneh ostalo še kaj raztopine v plastenki, morate to raztopino zavreči v skladu z lokalnimi predpisi ali vrniti nazaj v lekarno.
Signs of osteonecrosis are joint stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty in movement. 
Znaki osteonekroze so togost sklepa, bolečine v sklepu (zlasti v kolku, kolenu in rami) in težave z gibljivostjo.
There are no clinically significant interactions when emtricitabine is co-administered with indinavir, zidovudine, stavudine, famciclovir or tenofovir disoproxil fumarate. 
Ni klinično pomembnih interakcij, ko se emtricitabin uporablja skupaj z: indinavirom, zidovudinom, stavudinom, famciklovirom ali dizoproksiltenofoviratom fumaratom.
The apparent volume of distribution after intravenous administration of emtricitabine was 1.4 ± 0.3 L/kg, indicating that emtricitabine is widely distributed throughout the body to both intracellular and extracellular fluid spaces. 
Po intravenozni uporabi emtricitabina je bil opažen volumen porazdelitve 1,4 ± 0,3 l/kg, kar nakazuje, da je emtricitabin v telesu široko distribuiran tako znotraj kot zunaj celičnega prostora.
Examples of body weight and the corresponding doses and volumes of the oral solution to be taken each day are given in the table below: 
Primeri telesne mase in pripadajočih odmerkov ter volumnov peroralne raztopine, ki jih je treba jemati dnevno, so navedeni v spodnji preglednici.
• If you have problems with your kidneys, your doctor may advise you to take Emtriva less frequently. 
• Če imate ledvične težave, vam bo zdravnik morda svetoval, da jemljete zdravilo Emtriva manj pogosto.
Thirteen percent of the emtricitabine dose was recovered in urine as three metabolites. 
13 % odmerka emtricitabina je iz urina izoliranega v obliki treh metabolitov.
Consequently, the use of emtricitabine in combination with lamivudine for the treatment of HIV infection cannot be recommended at this time. 
Zaradi tega uporaba emtricitabina v kombinaciji z lamivudinom za zdravljenje okužbe z virusom HIV za sedaj še ni priporočljiva.
If you do miss a dose of Emtriva within 12 hours of when it is usually taken, take it as soon as you can, and then take your next dose at its regular time. 
Če ste pozabili vzeti odmerek zdravila Emtriva v roku 12 ur od časa, ko ga običajno vzamete, ga vzemite čim prej in nato vzemite naslednji odmerek ob običajnem času.
In the adult studies, 1,039 treatment-naïve and 440 treatment-experienced patients received emtricitabine (n = 814) or comparator medicinal product (n = 665) for 48 weeks in combination with other antiretroviral medicinal products. 
V študijah z odraslimi bolniki je 1.039 bolnikov, ki se zdravijo prvič, in 440 bolnikov, ki se zdravijo že dalj časa, prejemalo emtricitabin (n = 814) ali primerljivo zdravilo (n = 665) 48 tednov v kombinaciji z drugimi protiretrovirusnimi zdravili.
Patients co-infected with HIV and HBV should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment with emtricitabine for evidence of exacerbations of hepatitis. 
Bolnike s hkratno HIV in HBV okužbo je potrebno pozorneje opazovati in opraviti potrebne klinične in laboratorijske teste še vsaj nekaj mesecev po prenehanju zdravljenja z emtricitabinom zaradi možnosti poslabšanja hepatitisa.
No human data on the effect of emtricitabine are available. 
Ni podatkov o učinkih emtricitabina za ljudi.
The mean plasma to blood concentration ratio was approximately 1.0 and the mean semen to plasma concentration ratio was approximately 4.0. 
Povprečna vrednost razmerja med plazemsko koncentracijo in koncentracijo v krvi je bila približno 1,0 in povprečna vrednost razmerja med koncentracijo v semenski tekočini in koncentracijo v plazmi je bila približno 4,0.
• Children and adolescents up to 18 years of age who weigh at least 33 kg and who are able to swallow hard capsules: one 200 mg hard capsule, each day with or without food. 
• Za otroke in mladino do 18. leta starosti, ki tehtajo najmanj 33 kg, in ki lahko pogoltnejo trdo kapsulo: ena 200 mg trda kapsula dnevno z ali brez hrane.